Collen Faddick and Gina Kastel from Faegre & Benson discuss specific examples of enhanced transparency expectations and the factors that contribute to them, and conclude with suggestions for compliance professionals to adapt to these changes.
This article, by Kenneth Yood and Christine Cohn of Sheppard Mullin, presents a summary of some of the key features in Senator Baucus’ health care bill that are particularly relevant to the drug industry and that merit close attention.
A recent program sponsored by the Seton Hall Law Center for Health and Pharmaceutical Law & Policy urged health care and life sciences companies to place a high degree of emphasis on developing and maintaining effective corporate compliance programs.
Scott Bruns and Kathleen Meriwether of Ernst & Young count down the top five compliance risks facing life sciences companies, including sales & marketing risks, the FCPA and IFRS, as well as supply-chain integrity and aggregate spend.
